Pantakind-40 40 mg Delayed release tablet
PDF Leaflet Revision Date: 12 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Short-term treatment of duodenal ulcer, gastric ulcer, reflux oesophagitis, and Zollinger-Ellison Syndrome.
Dosage (summary)
40 mg once daily for 2-8 weeks; 80 mg for Zollinger-Ellison Syndrome.
Onset of Action / Duration
Onset: 30 mins, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; excreted in breast milk.
Key Drug Interactions
- Atazanavir
- Nelfinavir
- Warfarin
- Clopidogrel
Contraindications
- Hypersensitivity to pantoprazole
- Severe liver impairment
- Children
Common side effects
- Headache
- Dizziness
- Nausea
- Diarrhea
Counselling Points
- Take before or during breakfast
- Report any persistent symptoms
- Monitor for signs of hypomagnesaemia
Serious warnings
- Monitor liver enzymes in hepatic impairment
- Risk of gastric malignancy
- Hypomagnesaemia
Important Disclaimer
The Pantakind-40 40 mg Delayed release tablet professional information leaflet below is the property of Rbc Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
